ESPR Esperion Therapeutics Forecast, Technical & Fundamental Analysis
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs... Show more
ESPR is expected to report earnings to fall 98.60% to 0 cents per share on August 04
Q2'26
Est.
$0.00
Q1'26
Missed
by $0.08
Q4'25
Missed
by $0.07
Q3'25
Missed
by $0.18
Q2'25
Beat
by $0.12
The last earnings report on May 08 showed earnings per share of -10 cents, missing the estimate of -2 cents. With 813.46K shares outstanding, the current market capitalization sits at 811.73M.
A.I.dvisor tells us that ESPR and ANIK have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESPR and ANIK's prices will move in lockstep.
Aroon Indicator for ESPR shows an upward move is likely
ESPR's Aroon Indicator triggered a bullish signal on June 22, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 195 similar instances where the Aroon Indicator showed a similar pattern. In of the 195 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on May 27, 2026. You may want to consider a long position or call options on ESPR as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ESPR advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for ESPR moved out of overbought territory on June 18, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 51 cases where ESPR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ESPR turned negative on May 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
ESPR broke above its upper Bollinger Band on June 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (79.619). P/E Ratio (0.000) is within average values for comparable stocks, (97.743). ESPR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.629). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (1.669) is also within normal values, averaging (96.439).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ESPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ESPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
